After a strong showing in Q1FY19 due to the base effect and currency tailwinds, we expect some consolidation in Q2 financials due to 1) higher base and 2) cost pressure that can be attributed to supply constraints from China and higher crude prices. These two factors are likely to dilute strong currency tailwinds. The I-direct healthcare universe is expected to register 10% YoY growth. Domestic formulations are likely to grow 5.6% YoY (select pack) due to high base owing to channel restoration in Q2FY18 post GST implementation. US revenues (select pack) are expected to grow 8%...